Yamikani Mbilizi

TL;DR: In this article, the use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30% compared with placebo.

TL;DR: The VOICE risk score showed modest performance in identifying women at the highest risk of HIV-1 acquisition over the course of 1 year and having a risk score $3 correlated with an HIV- 1 incidence of .3% per year, which may represent a valuable tool to assist with targeted PrEP delivery in countries, such as South Africa and Kenya, that are in the process of scaling-up access to PrEP.

TL;DR: Dapivirine use in the periconception period does not seem to be associated with adverse effects on pregnancy or infant outcomes, and these findings provide support for additional safety studies of the dapvirine ring throughout pregnancy.

TL;DR: Encouraging support groups for MSM and TGW as well as training and sensitizing healthcare staff, and the general community, on MSM andTGW health issues and cultural competence may reduce stigma, improve access to healthcare, which could ultimately reduce HIV transmission.

TL;DR: In this article, the authors assessed HIV incidence and its correlates among men who have sex with men (MSM) and transgender women (TGW) in sub-Saharan Africa (SSA).